Cipla Limited (CIPLA) announces a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to Keytruda® in the US.
Cipla Limited (NSE: CIPLA) partners with S BP Group for exclusive licensing of best-in-class HER2 bispecific ADC, aiming to enhance breast cancer treatment i.
Cipla Limited (CIPLA) achieves highest-ever quarterly revenue of INR 7,119 Cr in Q1FY27, driven by strong market performance.
Cipla Limited (CIPLA) announced its Q4 FY26 results with robust growth in One India, North America, and One Africa segments.